Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Chinese kids with hodgkin lymphoma get tailored chemo combo in new trial

NCT ID NCT04726501

First seen Mar 21, 2026 · Last updated Jun 20, 2026 · Updated 18 times

Summary

This phase 4 study tests a modified chemotherapy regimen (based on a U.S. protocol) in 200 Chinese children and teens with newly diagnosed Hodgkin lymphoma. Depending on risk level, patients receive 4 to 6 cycles of chemotherapy, with or without low-dose radiation. The goal is to see if this approach improves event-free and overall survival compared to past outcomes in China.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

    Nanjing, China

  • Shanghai Children's Medical Center

    Shanghai, 200127, China

  • West China Second University Hospital, Sichuan University, Chengdu, China

    Chengdu, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Combination chemotherapy (AVE-PC or ABVE-PC) with or without involved-field radiotherapy

What this could lead to

If successful, this could confirm that a modified COG protocol works well for Chinese children with Hodgkin lymphoma, potentially improving event-free and overall survival rates.

What could go wrong

This is a single-country, non-randomized study with a relatively small sample size (200 participants). Results may not apply to other populations, and chemotherapy carries risks like infection and organ damage.

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.